medigraphic.com
ISSN 1025-0255 (Electronic)

2015, Number 6

<< Back Next >>

AMC 2015; 19 (6)

Results of Heberprot-P® in patients with diabetic foot ulcers

González RR, Cardentey GJ, Casanova MMC

Language: Spanish
References: 20
Page: 590-598
PDF size: 455.36 Kb.


ABSTRACT

Background: diabetic foot syndrome is one of the chronic complications that cause more morbidity and disability in diabetic patients, nowadays. The high amputation rates cause a significant degree of disablement with high economic and social costs. It has been proved that the administration of Heberprot-P® stimulates the granulation tissue formation in the bed of the wounds, as well as the secondary intention closure.
Objective: to describe the results of Heberprot-P® in patients with diabetic foot ulcers in Raúl Sánchez Policlinic in Pinar del Río municipality, Pinar del Río.
Methods: a descriptive, prospective study was conducted in 23 patients with the diagnosis of diabetic foot ulcer. The study was carried out from January, 2014 to February, 2015 in Raúl Sánchez Policlinic. The patients underwent an intralesional treatment with epidermal growth. They were studied taking into account their age, sex, personal pathological history, severity degree according to Wagner's classification, the doses and number of applications, the evaluation of the response and the side effects.
Results: patients between 50 and 59 years old (47, 8 %) predominated in the group studied, as well as female sex and diabetes mellitus type II. The cases with II degree plantar ulcers received the greatest number of applications of the medicine. A full granulation was achieved in the 78, 2 % of the cases and a partial granulation in the 17, 3 %. There was not need of amputations and none of the patients died.
Conclusions: with the use of Heberprot-P®, a favorable evolution was achieved in most of the cases. The integrity of the limb and its function could be kept in most of the patients.


REFERENCES

  1. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care [Internet]. 2012 Jan [citado 2 Sept 2014];35 Suppl 1:[aprox. 7 p.]. Dis-ponible en: http://care.diabetesjournals.org/content/35/Supplement_1/S64.extract

  2. Fernández-Montequín JI, Betancourt BY, Leyva-Gonzalez G, Mola EL, Galán-Naranjo K, Ramírez-Navas M, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to com-plete wound closure. Int Wound J. 2009;6(1):67-72.

  3. Conesa González AJ, Diaz Diaz O, Conesa del Rio JR, Domínguez Alonso JE. Mortali-dad por Diabetes mellitus y sus complica-ciones. Ciudad de la Habana, 1990-2002. Rev Cub Endocrinol. 2010;21(1):35-50.

  4. Ministerio de Salud Pública. Mortalidad por Diabetes mellitus. Anuario Estadístico de Salud 2014. La Habana: Dirección Nacional de Registros Médicos y Estadísticas de Sa-lud; 2014.

  5. González Fernández RS, Crespo Valdés N, Crespo Mojena N. Características clínicas de la diabetes mellitus en un área de salud. Rev Cubana Med Gen Integr [Internet]. 2000 [citado 12 Mar 2013];16(2):[aprox. 11 p.]. Disponible en: http://bvs.sld.cu/revistas/mgi/vol16_2_00/mgi07200.htm

  6. Meaney B. Diabetic foot care: prevention is better than cure. J Ren Care. 2012;38 Suppl 1:90-8.

  7. Sun JH, Tsai JS. Risk factors for lower ex-tremity amputation in diabetic foot disease categorized by Wagner classification. Dia-betes Res Clin Pract. 2012;95(3):358-63.

  8. Bekker-Mendez C, Guzman-Aguilar RM. TUNEL-positive cells in the surgical border of an amputation due to infected diabetic foot. Mol Med Report. 2012;5(2):363-72.

  9. Alexiadou K, Doupis J. Management of dia-betic foot ulcers. Diabetes Ther. 2012;3(1):4.

  10. Bakker K, Schaper NC. The development of global consensus guidelines on the man-agement and prevention of the diabetic foot 2011. Diabetes Metab Res Rev. 2012 Feb;28 Suppl 1:116-8.

  11. Balingit PP, Armstrong DG, Reyzelman AM, Bolton L, Verco SJ, Rodgers KE, et al. Nor-Leu3 -A(1-7) stimulation of diabetic foot ulcer healing: Results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial. Wound Re-pair Regen [Internet]. 2012 [citado 12 Mar 2013];20(4):[aprox. 8 p.]. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1524-475X.2012.00804.x/full

  12. Bakker KJ. Practical guidelines on the man-agement and prevention of the diabetic foot 2011. Diabetes Metab Res Rev. 2012;28(Suppl 1):225–31.

  13. Margolis DJ, Malay DS, Hoffstad OJ. Preva-lence of diabetes, diabetic foot ulcer, and lower extremity amputation among Medi-care beneficiaries, 2006 to 2008: Data Points#1. Data Points Publication Series [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 [actualizado 17 Feb 2011; citado 12 Mar 2013]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK63602/

  14. Marinello Roura J, Blanes Mompó I, Escude-ro Rodríguez JR, Ibáñez Esquembre V, Ro-dríguez Olay J. Tratado de Pie Diabético. Barcelona: Centro de Documentación del Grupo Esteve; 2002.

  15. Rivero Fernández F. Experiencias del Pro-grama de atención integral a pacientes con pie diabético en el estado Zulia, Venezuela. Biotecnol Apl [Internet]. 2010 Abr-Jun [citado 12 Mar 2013];27(2):[aprox. 3 p.]. Disponible en: http://scielo.sld.cu/scielo.php?pid=S102728522010000200004&script=sci_arttext

  16. Monteiro-Soares M, Boyko J, Ribeiro J, Ri-beiro I, Dinis-Ribeiro M. Risk stratification systems for diabetic foot ulcers: a system-atic review. Diabetología. 2011;54:1190–9.

  17. Zaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and dia-betic foot ulcers. Clin Interv Aging. 2007;2(1):93-8.

  18. Alexiadou K, Doupis J. Management of dia-betic foot ulcers. Diabetes Ther. 2012;3(1):4.

  19. Bekker-Mendez C, Guzman-Aguilar RM. TUNEL-positive cells in the surgical bor-der of an amputation due to infected dia-betic foot. Mol Med Report. 2012;5(2):363-72.

  20. Fernández Montequín J, Gabriela Mena-Violante H, Fernández Santiesteban L. Tratamiento y recuperación del pie diabé-tico grado 5 de la clasificación de Wagner tras aplicar el Heberprot-P. Bio-tecnol Apl [Internet]. 2010 [citado 12 Mar 2013];27(2):[aprox. 3 p.]. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S102728522010000200005&lng=es&nrm=iso




2020     |     www.medigraphic.com